1	Effects of successful percutaneous coronary intervention of chronic total occlusions with
2	demonstrable viability or ischemia: A protocol for a systematic review
_	
3	

- 4 Luís Leite^{1,2,3,4}*¶, Tomás Carlos¹¶, Gustavo Campos¹, Helena Donato⁵, Rodolfo Silva^{2,3,4}, Antero
- 5 Abrunhosa^{2,4}, Lino Gonçalves^{1,3,6}, Maria João Ferreira^{1,2,3,4}
- 7 1 Cardiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- 8 2 Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra,
- 9 Portugal

- 10 3 Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 4 Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Coimbra,
- 12 Portugal

16

20

22

- 5 Documentation and Scientific Information Service, Centro Hospitalar e Universitário de
- 14 Coimbra, Coimbra, Portugal
- 6 Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal
- * Corresponding author
- 18 E-mail: luispcleite@gmail.com
- 19 ORCID: 0000-0002-8493-6935
- 21 These authors contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Background

Chronic coronary total occlusion (CTO) is a common finding in patients referred to coronary angiography. To sustain blood flow distally to the occlusion site, collateral circulation is formed from preexisting vessels. While these collaterals may partial or completely preserve perfusion at rest, they may be insufficient when increased blood flow is needed. According to current guidelines, percutaneous coronary intervention (PCI) is recommended solely in patients with resistant angina despite optimal medical therapy or when a large area of documented ischemia in the territory of the occluded vessel is present. Randomised controlled trials (RCTs) suggest its benefit in the improvement of patients' quality of life and symptoms, despite their conflicting results concerning prognosis and left ventricular function. However, most of these studies often lack data regarding myocardial ischemic burden and viability, assessed by imaging methods. Therefore, the purpose of the systematic review is to comprise and analyse the literature on whether viability or ischemia-guided PCI of CTO, identified by imaging methods, has an impact on the clinical outcomes of the patients.

Methods

We will conduct a thorough research in different databases, including PubMed/MEDLINE,

EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core

Collection, Clinical trials in the European Union, and ClinicalTrials.gov. We will include RCTs.

Collection, Clinical trials in the European Union, and ClinicalTrials.gov. We will include RCTs,

cohort studies, cross-sectional studies, and case-control studies, in which patients with established

CTO were tested for viability and/or ischemia before the decision to perform PCI and were

evaluated by post-intervention testing or clinical endpoint follow-up. Two authors will

independently review the selected studies, and any discrepancies will be solved by a third element.

Subsequently, data from the various eligible studies will be extracted and analysed by two

different authors. No subgroup analysis is planned.

Ethics and disclosure: Ethical approval will not be required for this study as it is an analysis of

previously published articles (i.e., secondary data). The results will be published in a peer-

reviewed journal.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

PROSPERO registration: CRD42023426858.

INTRODUCTION

Chronic total coronary occlusions (CTO) are defined as angiographic evidence of complete vessel occlusion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 within an epicardial coronary artery, and an estimated duration of at least three months [1]. Its prevalence is not entirely established, with reporting rates varying from 16%-18% [2] to approximately 30% [3,4] in patients referred for coronary angiography. Notably, within the subgroup diagnosed with stable angina pectoris, it is believed that up to one fourth of this population exhibit this type of coronary disease [5]. In the presence of a CTO, blood supply to the myocardium is solely from collateral vessels. The development of a collateral circulation network is a complex physiologic response induced by the chronic state of hypoxia, by the pressure gradient created, as well as by several different humoral factors. There is an individual variation on the ability to develop well-formed collaterals that may avoid a transmural myocardial infarction and preserve ventricular function. However, it is widely believed that, although the collateral network may have the ability to preserve perfusion at rest, it could be insufficient when increased blood flow is needed [4]. Moreover, the chronic supply defect from the main artery may cause myocardium hibernation, characterized by reversible reduced regional contractile function that could partial or completely recover after reperfusion or revascularization [6,7]. Bearing this in mind, it would be reasonable to refer these patients to percutaneous coronary intervention (PCI). Nonetheless, current guidelines, prevailing since 2018, recommend CTO PCI only in patients with angina resistant to

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

optimal medical therapy or with a large area of documented ischemia in the territory of the occluded vessel (with a class of evidence IIa) [8]. Until recently, there was reluctance in attempting PCI in CTO patients, with solely an estimate 10%-15% of all eligible CTO lesions being referred [9,10]. This was based on lower procedural success and high rate of complications, such as urgent coronary artery bypass graft (CABG) surgery, coronary perforation, acute reocclusion, collateral loss and major adverse cardiac events, including death [11]. During the past decade, important developments in interventional materials and techniques have led to the achievement of high rates of procedural success, defined as a residual stenosis <30% with antegrade TIMI flow grade 3 in the CTO target vessel [12,13]. Indeed, recent studies such as the EXPLORE trial, suggested that PCI of CTO was safe even in patients with a concurrent ST-elevation myocardial infarction (STEMI) in other main artery, with no periprocedural death or emergency CABG [14]. Also, evidence suggests that the higher mortality and morbidity found in patients with multivessel disease, in comparison to single-vessel disease, might be partially attributed to the presence of concomitant CTO, contributing to the declining of LV function [15]. Hence, it urges to clearly define which patients are candidates for PCI on top of optimal medical therapy (OMT), since currently we have no accurate method that predicts who will benefit from that [16]. In the past few years, randomized clinical trials (RCTs) have focused on evaluating whether CTO-PCI in addition to OMT improved patients' symptoms and prognosis. Overall, it is generally accepted that it improves patients' quality of life and symptoms, mainly angina and physical exercise limitation, when compared to no PCI [16-20]. DECISION-CTO trial was one of the few studies that did not show this relative benefit [21]. However, in this study, revascularization of non-CTO lesions was performed after randomization in OMT+CTO-PCI or solely OMT, potentially contributing to the absence of differences [20]. When prognosis and LV function are concerned, studies show more conflicting results. In a subgroup analysis of the EXPLORE trial, Elias et al. demonstrated that in the dysfunctional segments afflicted by the chronic occlusion, PCI was associated with marked improvement of regional function, measured by cardiac magnetic resonance imaging (cMRI), especially if transmural extent of infarction (TEI) was lower than 50% [22]. Different research using cMRI suggested that in segments with TEI below 75% there was a tendency for improvement in segmental wall thickening (SWT), and that the extent of improvement in LV ejection fraction (LVEF) correlated with the size of infarcted area before procedure [23]. However, mean LVEF remained practically unchanged, with the same finding being observed in the COMET-CTO trial [20]. Furthermore, REVASC trial showed no differences in regional wall motion of the myocardium affected by the CTO lesions after PCI [24]. Moreover, IMPACTOR-CTO trial evaluated the impact of PCI on the composite endpoint of all-cause death, myocardial infarction, and unplanned revascularization six months after the procedure, with no significant differences described [17]. Lastly, OAT-trial demonstrated a tendency for reinfarction in the PCI group, at a follow-up time of approximately four years [25]. In the published RCTs there are very few data regarding myocardial ischemic burden and viability, often assessed by imaging methods, such as cMRI, single-photon emission computed tomography (SPECT), stress echocardiography or positron emission tomography (PET). Currently, ISCHEMIA-CTO trial is underway to evaluate whether CTO-PCI improves quality of life and major adverse cardiovascular events in patients with significant ischemic burden [26]. To the best of our knowledge, a systematic review of the literature on whether viability or ischemia-guided PCI of CTO have an impact in clinical outcomes is yet to be conducted. We aim to address this subject, evaluating all-cause mortality, nonfatal myocardial infarction, symptomatic improvement, and ischemic burden reduction in the follow-up of patients with documented viability or ischemia previously to the decision to perform PCI.

METHODS AND ANALYSIS

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

The protocol and completed systematic review will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Protocols and the Prisma checklists, respectively.

Eligibility criteria

In this systematic review, our objective is to identify RCTs, cohort studies (prospective or retrospective in nature), cross-sectional studies, and case-control studies, in which patients with established CTO were tested for viability and/or ischemia before the decision to perform PCI and were evaluated by post-intervention testing or clinical endpoint follow-up. The diverse testing modalities encompassed cMRI, PET, SPECT or stress echocardiography. Studies lacking viability and/or ischemia testing before PCI or lacking measured clinical endpoints or post-intervention testing will be excluded. Table 1 presents our PICO description. If the same study is represented in different articles, the one with the largest sample size or more suitable data for our specific aim will be selected. No restriction regarding publication year will be set; therefore, we will be including studies from inception to the 31st of October 2023. There will be no restrictions on publication status or language of publication. We will resort to a professional translator if needed.

Table 1. PICO description

Abbreviation	PICO	Elements
P	Population	Patients with a CTO who had performed viability or ischemia exams before the decision to perform PCI, with a post-intervention clinical evaluation and/or cardiac testing (LV function, ischemia burden evaluation)
I	Intervention	Successful PCI with documented viability or ischemia
С	Comparator	Patients with a CTO who had no demonstrable viability or ischemia before performing successful PCI, had

		demonstrable viability or ischemia but have not performed
		PCI or in whom PCI was unsuccessful
		All-cause mortality, nonfatal myocardial infarction,
О	Outcome	symptomatic improvement, left ventricular function
		improvement, and ischemic burden reduction

Information sources

We will comprise literature published in the following databases: PubMed/MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core Collection, and we will also consult Clinical trials in the European Union, and ClinicalTrials.gov to check for ongoing or unpublished trials. If any relevant unpublished trial is found, the corresponding author listed will be contacted to grant access to the required information. If no response is given or the author decides not to share the data, this will be listed as the reason for excluding such a trial Grey literature will also be queried to include all possible articles on the subject. We will also hand search in the reference list of the included articles. No pre-prints will be included.

Search strategy

Detailed search strategies will be conducted in the previously described databases, in consultation with a medical librarian with expertise in systematic review searching. The search strategy will contain controlled vocabulary (e.g., Medical Subject Headings (MeSH)) and text words searches adapted to each one of the databases regarding its own special requirements. To merge the search terms effectively, Boolean operators "AND" and "OR" will be used. An example of the search strategy used in PubMed/MEDLINE is depicted in Table 2.

Table 2. Search strategy

163

PubMed	PubMed/MEDLINE					
Query	Search					
	(Coronary Occlusion[Title/Abstract]) AND (chronic[Title/Abstract]))) OR (((
Д1	"Coronary Occlusion/diagnosis" [Mesh] OR "Coronary Occlusion/diagnostic					
#1	imaging"[Mesh] OR "Coronary Occlusion/therapy"[Mesh])) AND "Chronic					
	Disease"[Mesh])					
	("Heart/diagnostic imaging"[Mesh] OR "Cardiac Imaging Techniques"[Mesh] OR					
	"Ventricular Function, Left"[Mesh] OR "Positron-Emission Tomography"[Mesh]					
	OR "Magnetic Resonance Imaging, Cine" [Mesh] OR "Adenosine" [Mesh] OR					
	"Contrast Media" [Mesh] OR "Dobutamine" [Mesh] OR "Gadolinium" [Mesh] OR					
	"Echocardiography"[Mesh] OR "Fibrosis"[Mesh] OR "Necrosis"[Mesh] OR					
	"Myocardial Ischemia" [Mesh] OR "Myocardial Stunning" [Mesh] OR "Ventricular					
	Dysfunction, Left"[Mesh]) OR (Cardiac Imaging Techniques[Title/Abstract] OR					
	Techniques, Intracardiac Imaging[Title/Abstract] OR Ventricular Function,					
#2	Left[Title/Abstract] OR Myocardial Perfusion Imaging[Title/Abstract] OR					
#2	Positron-Emission Tomography[Title/Abstract] OR Positron Emission					
	Tomography Computed Tomography[Title/Abstract] OR Magnetic Resonance					
	Imaging Cine[Title/Abstract] OR Adenosine[Title/Abstract] OR Contrast					
	Media[Title/Abstract] OR Dobutamine[Title/Abstract] OR					
	Gadolinium[Title/Abstract] OR Echocardiography[Title/Abstract] OR					
	Echocardiography, Stress[Title/Abstract] OR Fibrosis[Title/Abstract] OR					
	Necrosis[Title/Abstract] OR Myocardial Ischemia[Title/Abstract] OR Ventricular					
	Dysfunction, Left[Title/Abstract] OR Myocardial Stunning[Title/Abstract] OR					
	Myocardial hibernation[Title/Abstract])					

	(Percutaneous Coronary Intervention[Title/Abstract] OR Angioplasty, Balloon,		
	Coronary[Title/Abstract] OR Atherectomy, Coronary[Title/Abstract] OR Cor		
#3	Revascularization, Percutaneous[Title/Abstract] OR Myocardial		
	Revascularization[Title/Abstract] OR "percutaneous coronary intervention"[MeSH		
	Terms] OR "Myocardial Revascularization"[Mesh])		
#4	Search #1 AND #2 AND #3		

Data management

All studies and literature reviewed will be imported to EndNote citation software and all duplicates will be removed.

Selection process

Two independent reviewers will conduct the selection phase of the studies during the month of January 2024. Any discrepancy found between the two reviewers will be solved by a third reviewer. The remaining studies will be full-text reviewed and included or excluded according to our predefined eligibility criteria. A flow chart similar to Fig. 1 will be presented to detail the study selection process for this review.

Fig. 1. Flowchart diagram presenting the selection process for the studies.

Data collection process

Data collection will be performed after the selection process. Two independent reviewers will extract the relevant data for our systematic review from the various eligible studies. A third reviewer will solve any found discrepancies and validate the other results.

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

Data items Collected data from the obtained studies will encompass authors' names, sample size, study design, number of eligible patients, average age, gender distribution, type of cardiac exam conducted pre and post intervention, decision to perform PCI or solely OMT, success of PCI, definition of myocardial ischemia and viability assessment for each study and type of clinical follow-up performed. Reasons for the exclusion of full text records will be reported. Details on the selection process of the studies and included patients will be documented into a flow chart, following PRISMA checklists. **Outcomes** Our systematic review aims to assess whether viability or ischemia-guided PCI of CTO have an impact on clinical outcomes. To achieve this, we will analyse diverse parameters across the different studies such as all-cause mortality, nonfatal myocardial infarction, symptomatic improvement, left ventricular improvement and ischemic burden reduction post PCI (successful vs non successful) or solely OMT. No subgroup analysis is planned at first hand; however, it may be performed if motivated by the literature review. Risk of bias Risk of bias of individual studies will be assessed independently by two reviewers, with a third reviewer assisting with any disagreements. Since we will be including diverse types of studies, we will use different tools to identify the risk of bias depending on each study's characteristics. We will use Cochrane Risk of Bias 2.0 –tool for assessing risk of bias in randomized trials, and ROBINS-I tool - Risk Of Bias In Non-randomized Studies - of Interventions.

206 **Data synthesis** 207 208 We will provide a narrative synthesis of the findings from the selected studies, structured around 209 the viability and/or ischemia exam, and type of clinical outcome measured. 210 211 Confidence in cumulative evidence The strength of the body evidence will be assessed using the Grading Recommendations 212 Assessment, Development and Evaluation (GRADE). 213 214 Patient and public involvement 215 216 This is a protocol for a systematic review based on previously published data. No participant 217 recruitment or involvement will be necessary. 218 219 **Ethics and dissemination** This systematic review will be conducted upon public and already published data; therefore, no 220 ethical approval is necessary. The resulting work will be published in a peer-reviewed journal and 221 222 presented at relevant conferences. Any necessary modifications of the protocol will be dated and 223 reported through a detailed description of the rationale for the adjustments. 224 225 **DISCUSSION** 226 Even though CTO are a common finding in patients with coronary artery disease, there are conflicting results regarding the benefit of performing PCI in these lesions. Most clinical studies 227

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

lack data regarding myocardial ischemia burden and viability documentation, therefore a systematic review on the clinical impact of ischemia/viability-guided CTO PCI is needed. This study has limitations as it is a secondary study dependent on the published data. Moreover, there are several imaging modalities to diagnose ischemia or viability, each one with its own criteria. On the other hand, the clinical impact of the intervention is measured with different outcomes within each study, which could make the discussion more demanding to perform. Therefore, we will provide a narrative synthesis of the findings, structured around the diagnostic exams and type of clinical outcome. **SUPPORTING INFORMATION** S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and Meta- Analysis Protocols) 2015 checklist: Recommended items to address in a systematic review protocol*. **AUTHOR CONTRIBUTIONS** Conceptualization: Luís Leite, Tomás Carlos, Maria João Ferreira. Investigation: Luís Leite, Tomás Carlos, Gustavo Campos, Lino Gonçalves, Maria João Ferreira. Methodology: Luís Leite, Tomás Carlos, Gustavo Campos, Helena Donato. Supervision: Maria João Ferreira. Writing – original draft: Luís Leite, Tomás Carlos, Gustavo Campos. Writing – review & editing: Luís Leite, Tomás Carlos, Gustavo Campos, Helena Donato, Rodolfo Silva, Antero Abrunhosa, Lino Gonçalves, Maria João Ferreira.

perpetuity.

It is made available under a CC-BY 4.0 International license.

250 Data Availability Statement: No datasets were generated or analyzed during the current study. All 251 relevant data from this study will be made available upon study completion. 252 253 Funding: The authors received no specific funding for this work. 254 255 Competing interests: The authors have declared that no competing interests exist. 256 REFERENCES 257 258 Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, et al. 1. 259 Recanalisation of Chronic Total coronary Occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012;8:139–45. 260 2. Azzalini L, Jolicoeur EM, Pighi M, Millán X, Picard F, Tadros VX, et al. Epidemiology, 261 Management Strategies, and Outcomes of Patients With Chronic Total Coronary 262 Occlusion. Am J Cardiol. 2016;118:1128-35. 263 264 Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 3. 265 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165. 266 267 4. Stuijfzand WJ, Driessen RS, Raijmakers PG, Rijnierse MT, Maeremans J, Hollander MR, et al. Prevalence of ischaemia in patients with a chronic total occlusion and 268 269 preserved left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging. 2017;18:1025-33. 270 271 5. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. 272 Current perspectives on coronary chronic total occlusions. J Am Coll Cardiol. 2012;59:991-7. 273 274 Heusch G. Myocardial stunning and hibernation revisited. Nat Rev Cardiol. 6. 2021;18:522–36. 275 276 7. Ferrari R, Ceconi C, Curello S, Benigno M, Canna G La, Visioli O. Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. J Cardiovasc 277 278 Pharmacol. 1996;28:18-26. 279 Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 8. 280 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 281 2019;40:87-165.

Grantham JA, Marso SP, Spertus J, House J, Holmes DR, Rutherford BD. Chronic Total Occlusion Angioplasty in the United States. JACC Cardiovasc Interv. 2009;2:479–86.

282

283

9.

perpetuity. It is made available under a CC-BY 4.0 International license .

10. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al.

Current Perspectives on Coronary Chronic Total Occlusions. J Am Coll Cardiol.

- 286 2012;59:991–7.
- 287 11. Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi L V, et al. Procedural
- outcomes and long-term survival among patients undergoing percutaneous coronary
- intervention of a chronic total occlusion in native coronary arteries: a 20-year
- 290 experience. J Am Coll Cardiol. 2001;38:409–14.
- 291 12. Christopoulos G, Karmpaliotis D, Alaswad K, Lombardi WL, Grantham JA, Rangan B
- V., et al. The efficacy of "hybrid" percutaneous coronary intervention in chronic total
- occlusions caused by in-stent restenosis: Insights from a US multicenter registry.
- 294 Catheter Cardiovasc Interv. 2014;84:646–51.
- 295 13. Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, et al.
- 296 Recanalisation of Chronic Total coronary Occlusions: 2012 consensus document from
- the EuroCTO club. EuroIntervention. 2012;8:139–45.
- Henriques JPS, Hoebers LP, Råmunddal T, Laanmets P, Eriksen E, Bax M, et al.
- 299 Percutaneous intervention for concurrent chronic total occlusions in patients
- 300 with STEMI. J Am Coll Cardiol. 2016;68:1622–32.
- 301 15. Claessen BE, van der Schaaf RJ, Verouden NJ, Stegenga NK, Engstrom AE, Sjauw KD,
- et al. Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term
- 303 Mortality and Left Ventricular Function in Patients After Primary Percutaneous
- Coronary Intervention. JACC Cardiovasc Interv. 2009;2:1128–34.
- 305 16. Rinfret S, Sandesara PB. Reducing ischemia with CTO PCI. JACC Cardiovasc Interv.
- 306 2021;14:1419–22.
- 307 17. Obedinskiy AA, Kretov EI, Boukhris M, Kurbatov VP, Osiev AG, Ibn Elhadj Z, et al.
- The IMPACTOR-CTO Trial. JACC Cardiovasc Interv. 2018;11:1309–11.
- 309 18. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A
- randomized multicentre trial to compare revascularization with optimal medical therapy
- for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39:2484–93.
- 312 19. Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the Early Health Status
- Benefits of Successful Chronic Total Occlusion Recanalization. Circ Cardiovasc Qual
- 314 Outcomes. 2010;3:284–90.
- 315 20. Juricic SA, Tesic MB, Galassi AR, Petrovic ON, Dobric MR, Orlic DN, et al.
- Randomized Controlled Comparison of Optimal Medical Therapy with Percutaneous
- Recanalization of Chronic Total Occlusion (COMET-CTO). Int Heart J. 2021;62:16–22.
- 318 21. Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized Trial
- 319 Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total
- 320 Occlusion. Circulation. 2019;139:1674–83.
- 321 22. Elias J, van Dongen IM, Hoebers LP, Ouweneel DM, Claessen BEPM, Råmunddal T, et
- al. Improved recovery of regional left ventricular function after PCI of chronic total
- 323 occlusion in STEMI patients: a cardiovascular magnetic resonance study of the
- randomized controlled EXPLORE trial. J Cardiovasc Magn Reson. 2017 Dec 19;19:53.

perpetuity.

It is made available under a CC-BY 4.0 International license .

325 23. Baks T, van Geuns RJ, Duncker DJ, Cademartiri F, Mollet NR, Krestin GP, et al. Prediction of Left Ventricular Function After Drug-Eluting Stent Implantation for 326 Chronic Total Coronary Occlusions. J Am Coll Cardiol. 2006;47:721-5. 327 Mashayekhi K, Nührenberg TG, Toma A, Gick M, Ferenc M, Hochholzer W, et al. A 328 24. Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation 329 330 in Chronic Total Occlusion. JACC Cardiovasc Interv. 2018;11:1982–91. 25. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. 331 332 Coronary intervention for persistent occlusion after myocardial infarction. N Engl J 333 Med. 2006;355:2395-407.

Råmunddal T, Holck EN, Karim S, Eftekhari A, Escaned J, Ioanes D, et al. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design. Am Heart J. 2023;257:41–50.

338




Figure 1